Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults With Fibrodysplasia Ossificans Progressiva

FRISCO, Tx… November 10, 2026 (GLOBE NEWSWIRE) — Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today that it was selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron’s FDA-approved product to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Approved August 19, 2026, Pasatru™ is the first and only treatment to demonstrate a reduction in both new HO lesions and clinician-assessed flare-ups in adults with FOP.

Soleo Health will assist eligible patients gain access to Pasatru™ by working with providers, patient assistance programs, and infusion support. Through its experienced Soleo-employed nurses and clinical support team, the Company will leverage its ultra-rare disease expertise to help streamline coordination of therapy.

“The addition of Pasatru™ to SoleoRare^®, our Rare Disease Specialty Pharmacy, underscores our commitment to bringing specialized care to the FOP community,” said Drew Walk, chief executive officer of Soleo Health. “We are pleased to be one of two select partners working with Regeneron to support the availability of this novel treatment and apply our rare disease expertise to help patients receive exceptional care.”